ZEUS Scientific Acquires Synthetic Peptides from Sheba Medical Center's Tech Transfer Co.
Oct 21, 2021
ZEUS Scientific Acquires Synthetic Peptides from Sheba Medical Center's Tech Transfer Co.
Could Hold the Clue to Creating Better Treatments for Rheumatoid Arthritis
ZEUS Scientific is defining the future of IFA testing
Sep 9, 2021
As a pioneer in indirect fluorescent antibody (IFA) technology, ZEUS has continually delivered quality products and expertise in autoimmune serology that laboratories have relied upon since 1976.
Meet the next generation in IFA imaging and pattern recognition, the ZEUS dIFine® digital immunofluorescence system. dIFine is an automated digital scanner with intelligent software, it is designed to acquire, analyze, display and store digital images of ZEUS HEp-2 IFA slides.*
What’s the catch to ZEUS Borrelia MTTT? No more Lyme disease immunoblots
Aug 26, 2021
Want to improve your laboratory’s detection of early Lyme disease (stage 1 and stage 2) by up to 30%?There is a catch!
See the ZEUS smart automation solution for SARS-CoV-2 antibody testing in action.
Aug 11, 2021
The expertise that ZEUS Scientific has gained from over 45 years of developing and manufacturing diagnostic tests was instrumental in creating the unique dual antigen design of the ZEUS ELISA SARS-CoV-2 Antibody Test Systems. Utilizing these tests with the Dynex AGILITY® fully automated ELISA system provides you with a powerful and simple combination for your testing needs. As the world continues to fight the COVID-19 pandemic, SARS-CoV-2 antibody testing remains an important tool.
Have a happy and safe Independence Day!
Jul 4, 2021
As our country slowly starts to get back to normal, we remember and cherish the high price of freedom. We appreciate you making the choice to be our customer, our partner, our employee and our friend.
Happy Independence Day!
ZEUS reviews the importance of an accurate diagnosis and treatment options for Lyme disease
Jun 10, 2021
Thank you for joining us for this Lyme Disease Awareness Month Educational Series. We hope you have benefited from the information provided either as a reminder for this Lyme disease season or as an opportunity to learn something new. In this final Lyme Disease Awareness Series installment, we focus on diagnosis and treatment options.
ZEUS wants to keep you safe this Lyme disease season - learn how
Jun 3, 2021
With National Lyme Disease Awareness Month behind us, let's focus on prevention.
The discovery of the bacterium responsible for Lyme disease and how it is carried specifically by deer ticks provides us with valuable information to help prevent Lyme disease. Proactive Lyme disease prevention and testing once you identify a tick or have symptoms is the key.
ZEUS ELISA™ SARS-CoV-2 IgG Test System Receives Expanded Automation Claims through FDA EUA
May 26, 2021
ZEUS Scientific has received Emergency Use Authorization (EUA) for additional automation claims from the U.S. Food and Drug Administration (FDA) for its in vitro ELISA diagnostic test for the qualitative detection of IgG antibodies to the SARS-CoV-2 virus in human serum and plasma. The ZEUS ELISA SARS-CoV-2 IgG Test System assay utilizes a dual antigen combination of recombinant S1 receptor binding domain (RBD) viral protein and recombinant nucleoprotein that detects immune responses that other antibody tests may miss.
ZEUS putting patients first - Lyme Disease Testing History
May 20, 2021
We continue our series during this year’s National Lyme Disease Awareness Month with a focus on the history of Lyme disease and how Lyme disease testing has evolved to improve early detection.
ZEUS Scientific Announces FDA Emergency Use Authorization Approval for our ELISA SARS-CoV-2 Total Antibody (IgG/IgM/IgA) Test System
May 17, 2021
ZEUS Scientific has been granted by the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its in vitro ELISA diagnostic test for the qualitative detection of total antibodies to the SARS-CoV-2 virus in human serum and plasma. ZEUS has been producing and shipping the ELISA SARS-CoV-2 Total Antibody Test System since June 2020 and has steadily increased production capabilities to keep up with the growing demand. Achieving EUA approval was the next step in ZEUS’s commitment to deliver superior quality COVID-19 antibody detection devices. The ZEUS ELISA SARS-CoV-2 Total Antibody Test System joins our previously EUA-approved ZEUS ELISA SARS-CoV-2 IgG Test System.
May is National Lyme Disease Awareness Month and ZEUS is committed to getting the word out
May 13, 2021
May is Lyme Disease Awareness Month, an important reminder for us all to be proactive to protect ourselves against Lyme disease, know the symptoms and if suspected get tested early using the newest and most accurate testing algorithm. To help raise awareness, we will be sharing information on Lyme disease, including key facts, testing, prevention, diagnosis and the importance of timely treatment.
Immunoblots getting you down? Make the switch to ZEUS Borrelia MTTT™
Apr 13, 2021
Are you still using immunoblots for your 2nd tier Lyme disease testing? Join the trend and eliminate blots altogether.
Immunoblots were never a lab favorite. In fact, most labs do not bother with them in-house and choose the costly send out option. Now there is a better way. Say good-bye to immunoblots and leave behind immunoblot insensitivity, subjectivity and all the related technical challenges while improving accuracy and boosting overall efficiency in your laboratory with a simple workflow.
The ZEUS smart automation solution for SARS-CoV-2 antibody testing
Mar 16, 2021
Now is the perfect time to partner with ZEUS Scientific for your SARS-CoV-2 antibody testing, and put the power of our dual antigen design to work in your laboratory with full automation right out of the box.
Lyme Disease Cases Are Increasing. Be prepared with ZEUS Borrelia MTTT™
Feb 12, 2021
Lyme disease is curable. The faster it is diagnosed and treated, the better the outcome for the patient. Missing a Lyme disease diagnosis can lead to long-term health repercussions for patients. Now is the perfect time to make the benefit-driven promise of a Borrelia MTTT algorithm a reality in your laboratory.
The ZEUS Dual Antigen Difference. Does your SARS-CoV-2 antibody test detect antibodies to both nucleocapsid protein and spike S1-RBD protein?
Jan 29, 2021
The ZEUS ELISA SARS-CoV-2 Test Systems are designed to detect antibodies against both the Nucleocapsid protein and the Spike protein S1-RBD and is optimized for superior sensitivity and specificity.
Let our Experts Help You Make the switch to ZEUS Borrelia MTTT™
Jan 13, 2021
Are you still using immunoblots or the discontinued MarDx® Lyme disease Western blot? If you are trying to figure out your transition plans, let us help convert to a more accurate Lyme disease testing algorithm!
Make the switch to ZEUS Borrelia MTTT™ - the complete solution for your Lyme-disease testing needs
Dec 17, 2020
Making the switch to the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm gives you improved detection of early Lyme disease, allows you to replace outdated Lyme disease immunoblots, and increases overall lab workflow and efficiency.
Preparing for an influx of antibody testing? ZEUS SARS-CoV-2 Test Systems are the answer.
Dec 11, 2020
Do you know someone who is wondering if they had COVID-19 and were asymptomatic? Are they thinking “Did I have COVID-19 and not realize it, was that short term cough due to allergies or did I have mild symptoms for COVID-19?”
2021 Lyme disease testing resolutions
Dec 3, 2020
With less than 30 days left of 2020, now is the time to get ready for the 2021 Lyme disease season by implementing ZEUS Scientific's Borrelia Modified Two-Tiered Testing (MTTT™) algorithm.
Antibiotic Awareness Week & the importance of accurate diagnostic test results
Nov 20, 2020
Help with the fight against antibiotic resistance. Accuracy matters.Early detection and appropriate treatment can make a world of difference.
Why ZEUS is the right choice for your ANA Hep-2 IFA testing
Nov 10, 2020
See the Quality Only ZEUS Can Deliver!
With over 40 years of experience, ZEUS Scientific continues to be a pioneer in immunofluorescence assay (IFA) technology delivering quality and expertise in ANA HEp-2 IFA testing that laboratories have relied on since 1978.
Why serological antibody testing is important for COVID-19 and how to use it
Oct 27, 2020
Antibody testing provides valuable information to help stop the spread of the virus.
Register for our webinar: Shifting the Paradigm in Lyme Disease Testing | Oct 29th, 10am EST
Oct 16, 2020
Learn about the history of Lyme disease and ZEUS’s Borrelia MTTT™ algorithm that led to a paradigm shift in Lyme disease testing
Join Us October 29th at 10am EST
ZEUS Scientific Announces FDA Emergency Use Authorization approval for our ELISA SARS-CoV-2 IgG Test System
Oct 7, 2020
ZEUS Scientific announced today, October 7, 2020 the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its in vitro ELISA diagnostic test for the qualitative detection of IgG antibodies to the SARS-CoV-2 virus in human serum and plasma. ZEUS has been producing and shipping the ELISA SARS-CoV-2 IgG Test System since early June 2020 and has steadily increased production capabilities to keep up with the growing demand. Achieving EUA approval was the next step in ZEUS’s commitment to deliver superior quality COVID-19 antibody detection devices.
Two Ways to Learn about ZEUS Borrelia MTTT
Oct 2, 2020
Missed the feature on the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm on Lifetime’s Access Health? Here’s your chance to see what everyone is talking about! Watch as Host Ereka Vetrini and Dr. Raymond Dattwyler, M.D. discuss the history of Lyme disease testing, and the importance of the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm, the breakthrough in early Lyme disease testing.
This Friday, on Lifetime's Access Health, Learn about Lyme Disease and the breakthrough ZEUS Borrelia MTTT™ Testing Algorithm
Sep 24, 2020
Are you ready to learn about a faster, easier, and more accurate way to test and diagnose early Lyme disease? Then tune in TOMORROW at 7:30am EDT* to Lifetime Network’s Access Health!
Learn about Lyme disease and the ZEUS Borrelia MTTT™ on Lifetime Network's Access Health Series September 25th at 7:30am ET*
Sep 11, 2020
Be sure to tune in to Lifetime network’s Access Health on September 25th, 2020 which will provide useful information on Lyme disease, with an emphasis on symptoms and the importance of testing featuring the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm.
Move Forward with Confidence
Sep 4, 2020
As the game continues to change in Lyme disease diagnosis, the MarDx™ Lyme Western blot assays are being discontinued by the manufacturer. Do not risk being left behind using an outdated Lyme disease testing algorithm. Stay up to date with ZEUS Borrelia MTTT™ algorithm, the only FDA cleared MTTT algorithm that eliminates the need for the confirmatory immunoblot test AND improves early Lyme Disease diagnosis.
ZEUS dIFine® the Next Generation in Digital IFA Imaging and Interpretation
Aug 27, 2020
ZEUS dIFine® is the next generation in IFA imaging and pattern recognition system. An automated digital scanner with intelligent software, it is designed to acquire, analyze, display and store digital images of ZEUS HEp-2 IFA slides*. ZEUS is taking your ANA IFA testing to the next level by pairing our top tier IFA ANA HEp-2 products with our dIFine™ system and quickly delivering positive/negative results and interpretation of 8 distinct ANA HEp-2 patterns.
ZEUS Borrelia MTTT™ to be Featured on Lifetime Network's Access Health Series
Aug 20, 2020
The word is getting out regarding how ZEUS Borrelia MTTT™ is improving early Lyme Disease diagnosis. Lifetime network will feature the only FDA cleared Borrelia Modified Two-Tiered Testing (MTTT) algorithm on their Access Health series scheduled to air on September 25th and October 3rd, 2020.
ZEUS dIFine® ANA Hep-2 IFA Submitted to FDA
Aug 14, 2020
The best slides deserve the best in class automation. We have completed the next step by submitting the ZEUS dIFine® to the FDA last month. We are taking your ANA IFA testing to the next level by pairing our IFA ANA Hep-2 with our dIFine® system.
ZEUS Borrelia MTTT™ improves Lyme patient outcomes during the summer of COVID-19
Aug 6, 2020
ZEUS Borrelia MTTT™ is a simpler, more cost effective, faster and better way to more accurately detect Lyme disease than using immunoblots. This updated algorithm detected up to 30% more positive patients in acute early Lyme disease, the critical time to correctly identify and treat!
Integrate COVID-19 Antibody Testing Simply & Effectively
Jul 31, 2020
While the world continues to deal with the COVID-19 pandemic, ZEUS recognizes the challenges facing resource strained labs as pre-pandemic test volumes rebound while absorbing the additional COVID-19 testing demands. ZEUS offers two SARS-CoV-2 antibody test systems which seamlessly integrates with our broad range of ELISA assays, spanning across autoimmune and infectious disease testing.
ZEUS Scientific Proven Performance Across our Menu of SARS-CoV-2 Antibody Test Systems
Jul 21, 2020
ZEUS has completed extensive performance testing of all of our devices using the same cohorts (total n=365) of clinically characterized patient samples.
NBC News highlights the benefits of Lyme MTTT
Jul 15, 2020
The ZEUS Borrelia MTTT™ algorithm was recently featured on the July 8th, 2020 NBC News Center Maine evening News. Read about it here!
ZEUS Scientific: American Expertise in Every American-Made Test
Jul 1, 2020
ZEUS Scientific Is a Proud American CompanyDoing our Part in the Fight Against COVID-19
We have a long history of developing, manufacturing and delivering IVD kits for infectious and autoimmune disease testing. With over 125 FDA cleared assays in our menu, we continue to apply our expertise of developing tests to detect human antibodies to a number of different viruses including SARS-CoV-2. For decades, laboratories have trusted ZEUS and now is the time to maintain confidence in ZEUS as we all continue the battle against the COVID-19 pandemic and SARS-CoV-2 virus.
ZEUS Scientific Now Offers a Comprehensive Menu of SARS-CoV-2 Antibody Test Systems
Jun 26, 2020
We now offer 3 separate SARS-CoV-2 antibody test systems across two methodologies testing for IgG, IgG/IgM and IgG/IgM/IgA which can be utilized individually or combined to implement an orthogonal testing algorithm for positive results to increase positive predictive value, all from the same manufacturer.
NEW! ZEUS ELISA SARS-CoV-2 Total Antibody Test System EUA Submitted, Validated, and Ready for distribution
Jun 15, 2020
ZEUS Scientific announced today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its in vitro ELISA diagnostic test for the semi-quantitative detection of Total (IgG, IgM, IgA) antibodies to the SARS-CoV-2 (novel 2019 Coronavirus) in human serum and plasma. ZEUS notified FDA that the test has been validated according to their guidelines established for serological assays, meeting the criteria to be distributed and is available now.
ZEUS Rapid SARS-CoV-2 IgM/IgG Antibody Test System: Delivering confidence in results
Jun 11, 2020
ZEUS Rapid SARS-CoV-2 IgM/IgG has been validated according to FDA guidelines established for serological assays, meeting the criteria to be distributed to where it is needed most. In response to the many inferior SARS-CoV-2 antibody tests flooding the market, the U.S FDA strengthened their data requirements to obtain an Emergency Use Authorization (EUA) for a COVID-19 antibody test. ZEUS immediately reacted by conducting a USA study of clinically characterized specimens that confirms the superior performance of our Rapid SARS-CoV-2 IgM/IgG Test System. ZEUS Scientific has heard your requests for help and is committed to providing quality easy-to-use solutions that will help address the public health threat posed by COVID-19.
ZEUS Scientific Announces NEW ZEUS ELISA SARS-CoV-2 IgG Test System
Jun 5, 2020
ZEUS Scientific announces today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its in vitro ELISA diagnostic test for the semi-quantitative detection of IgG antibodies to the SARS-CoV-2 (novel 2019 Coronavirus) in human serum and plasma. ZEUS has notified FDA that the test has been validated according to their guidelines established for serological assays, meeting the criteria to be distributed and is available now.
Let us put 40+ years of diagnostic experience to fight COVID-19 with you
May 27, 2020
In this time of crisis, we are here to help. For over 40 years ZEUS Scientific has developed, manufactured and sold in vitro diagnostic test kits for infectious and autoimmune disease testing. We have allocated the majority of our resources to produce serological antibody tests to combat the SARS-CoV-2 virus. For decades, many of our products were built to detect human antibodies to a number of different viruses and we have now applied that knowledge to help in the fight with the COVID-19 pandemic.
Specificity Matters when Selecting a SARS-CoV-2 Antibody Test
May 20, 2020
ZEUS Rapid SARS CoV-2 IgM/IgG Antibody Test System delivers with over 98% Specificity and no demonstrated cross reactivity to other coronaviruses.
Automated SARS-CoV-2 Antibody Tests
May 14, 2020
COMING SOON: ZEUS ELISA SARS CoV-2 Test System!
- Do you have serological samples from confirmed PCR-positive COVID-19 patients?
- Can we collaborate to validate assay performance for SARS-CoV-2 antibody testing?
Now Shipping! ZEUS Rapid SARS-CoV-2 Antibody Test
May 8, 2020
ZEUS Rapid SARS-CoV-2 IgM/IgG is validated, in stock and available to ship immediately.
ZEUS Rapid SARS-CoV-2 IgM/IgG Antibody Test System Validated, Ready for Distribution
Apr 30, 2020
On April 28th, 2020 ZEUS Scientific officially notified the U.S. FDA that it has validated the ZEUS Rapid SARS-CoV-2 IgM/IgG Test System and intends to begin distributing this product to laboratories.
ZEUS Scientific Announces NEW RAPID SARS-CoV-2 IgM/IgG Antibody Test System
Apr 22, 2020
ZEUS Scientific announces today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its rapid, in vitro diagnostic test for the qualitative detection of IgG and/or IgM antibodies to the SARS-CoV-2 (novel 2019 Coronavirus).
Important Update Regarding COVID-19 and ZEUS Scientific
Apr 13, 2020
In this troubled time, know you can count on the ZEUS Scientific team to be here for you. We remain fully operational to meet all your laboratory testing needs. Read on to learn about our COVID-19 response.
FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses
Jul 30, 2019
Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared today are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process in which a separate protein test called a Western Blot must be run after the initial EIA test.
ZEUS Scientific announces U.S. FDA 510(k) clearance of its ZEUS Borrelia Modified Two-Tiered Testing™ (MTTT) algorithm, a paradigm shift in laboratory testing for Lyme disease
Jul 29, 2019
ZEUS Borrelia MTTT™ algorithm has been shown to significantly improve the detection of early Lyme disease with increased sensitivity over the current standard two-tiered testing (STTT) algorithm.
ZEUS Scientific to offer its ZEUS IFA™ product line directly to customers in the United States
Dec 10, 2018
ZEUS Scientific has announced that as of January 1st, 2019, ZEUS will assume all sales, marketing and support functions for all ZEUS IFA™ Test Systems in the United States, its territories and possessions and Puerto Rico. On this date, laboratories, hospitals, universities and any other United States based facilities can begin to order these products directly from ZEUS Scientific. For more information on how to contact ZEUS Scientific visit: www.zeusscientific.com/contact-us.
Dynex® Technologies announces global partnership with ZEUS Scientific
Jul 27, 2018
Dynex Technologies has finalized a supply agreement with ZEUS Scientific (Branchburg, NJ) enabling ZEUS to sell Dynex instruments to the global clinical market. This new direct partnership builds on the long standing relationship between both companies with Dynex Technologies’ industry proven DS2®, DSX® and Agility® automated ELISA instrumentation and ZEUS Scientific’s broad range of ZEUS ELISA™ Test Systems which use common reagents and universal protocols across a diverse autoimmune and infectious disease menu.
ZEUS Scientific to offer its ZEUS ELISA™ product lines directly to customers in the United States
Dec 20, 2017
ZEUS Scientific has announced that as of February 1st, 2018, ZEUS will assume all sales, marketing and support functions for all ZEUS ELISA™ Test Systems in the United States, its territories and possessions and Puerto Rico. On this date, laboratories, hospitals, universities and any other United States based facilities can begin to order these products directly from ZEUS Scientific. For more information on how to contact ZEUS Scientific visit: www.zeusscientific.com/contact-us.
ZEUS Scientific announces U.S. FDA Premarket Approvals (PMA) and launch of its ZEUS ELISA™ Parvovirus B19 Test Systems
Sep 21, 2017
ZEUS Scientific announces the launch of ZEUS ELISA Parvovirus B19 IgG and IgM Test Systems, following receipt of Premarket Approvals (PMA) from the U.S. Food and Drug Administration (USFDA). ZEUS ELISA Parvovirus B19 Test Systems are the latest addition to the company’s market leading range of infectious disease diagnostic solutions with seamless integration into the ZEUS ELISA menu of Test Systems. These test systems feature universal reagents and protocol, assay protocol with more flexible incubation times than any other currently available ELISA method, and quick adoption into the lab due to minimal training, enabling in-house testing.
ZEUS Scientific Assumes All Support Functions for AtheNA Multi-Lyte Test Systems
Jul 19, 2016
As of June 14th, 2016, ZEUS Scientific has assumed all the sales, marketing and support functions for all of the AtheNA Multi-Lyte test systems, instruments and consumables for our customers based in the United States. Contact ZEUS directly to find out more about how these multiplex, fluorescent, bead-based assays offer a simple and efficient testing alternative. Be sure that no well is missed with SAVe Diluent(TM), and discover how our proprietary Intra-Well Calibration Technology(R) reduces the number of non-reportable wells in every run to maximize your value in choosing this unique platform!
AMA Adds New CPT Code for SPLA2-IIA Measurement for Cardiovascular Risk Assessment
Jul 23, 2015
ZEUS Scientific has been notified by the American Medical Association (AMA) that the Current Procedural Terminology (CPT) Editorial Panel has accepted its request to add code 0423T to report a test for measurement of secretory type II phospholipase A2 (sPLA2-IIA) protein for assessment of level of risk for cardiovascular event. The code has been posted to the AMA CPT website with an effective implementation date of January 1, 2016.
ZEUS Scientific Expands Cardiology Product Menu With Updated Agreement With Gamma Therapeutics
Jun 4, 2015
ZEUS Scientific and Gamma Therapeutics announced today that they have signed a new agreement providing ZEUS exclusive, worldwide rights to distribute, market and sell the GammaCoeur CVD Risk ELISA test.
ZEUS Scientific Expands ELISA Product Menu With Acquisition of Hama Detection Laboratory Tests
May 26, 2015
ZEUS Scientific announced today that it has finalized an agreement to purchase all right, title, and interest in the ImmuSTRIP HAMA IgG and ImmuSTRIP® HAMA Fragment ELISA kits from Immunomedics, Inc. (NASDAQ: IMMU).
ZEUS Scientific Appoints Corporate Counsel
Jul 24, 2013
ZEUS Scientific, a leading in vitro diagnostic solution provider, is pleased to announce the appointment of Wilentz, Goldman & Spitzer P.A. as its corporate counsel.